← All trials
NCT06142552
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2023
- Primary completion
- Dec 31, 2023
- Completion date
- Jan 31, 2026
- First posted
- Nov 21, 2023
- Last posted
- Nov 21, 2023
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu Gensciences lnc.Lead sponsor
- Chinese Academy of Medical SciencesStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.